Jardiance vs Farxiga: What to Do When One Fails

Why These Two Drugs Are Often Compared

Empagliflozin and dapagliflozin are the two most prescribed SGLT2 inhibitors in the United States. Both block the sodium-glucose cotransporter-2 in the proximal tubule, forcing roughly 60 to 90 g of glucose into the urine daily and lowering HbA1c by approximately 0.5 to 0.8% from baseline at standard doses [1]. Because they share a mechanism, clinicians and patients frequently ask whether failure of one means the other is equally ineffective, or whether a switch carries real clinical value.

The short answer is nuanced. Mechanism-based failure, meaning insufficient glycemic response at full dose, transfers between agents. Tolerability failure, meaning genital mycotic infections, volume depletion, or urinary symptoms, may not transfer if a different drug achieves lower drug-tissue concentrations or is taken at a different time of day.

Shared Mechanism, Different Trial Portfolios

EMPA-REG OUTCOME (N=7,020) randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg or 25 mg versus placebo. The primary endpoint, a three-point MACE composite, was reduced by 14% (hazard ratio 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority and P=0.04 for superiority) [2]. Cardiovascular death was cut by 38%.

Dapagliflozin's cardiovascular outcomes trial, DECLARE-TIMI 58 (N=17,160), did not show superiority for MACE but demonstrated a 27% reduction in the HF hospitalization or CV death endpoint among patients with established CVD [3].

Indications That Actually Differ

The FDA has approved these agents for overlapping but not identical indications. As of 2024, empagliflozin (Jardiance) carries approval for type 2 diabetes glycemic control, reduction of CV death in adults with T2D and established CVD, heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) [4]. Dapagliflozin (Farxiga) holds approval for T2D glycemic control, HFrEF, chronic kidney disease (CKD) not requiring dialysis, and reduction of eGFR decline in CKD [5].

This distinction matters at the bedside. A patient on Jardiance for HFpEF who experiences intolerable side effects cannot simply switch to Farxiga for the same indication, because Farxiga lacks an FDA HFpEF approval.

Defining "Failure": Three Distinct Scenarios

"Failure" is not a single event. Clinicians should categorize the type of failure before making any switching decision, because the category determines the next logical step.

Scenario 1: Glycemic Failure

Glycemic failure means the drug was taken consistently at the maximum tolerated dose for at least 12 weeks and HbA1c did not fall by at least 0.5 percentage points. Glycemic failure of one SGLT2 inhibitor is essentially a class failure. The SGLT2 transporter is the same molecular target, and no published head-to-head trial has demonstrated one agent achieving meaningful glycemic response after the other failed [6].

In this scenario, switching from Jardiance to Farxiga (or vice versa) is unlikely to produce a different HbA1c outcome. The 2023 ADA Standards of Care recommend adding a GLP-1 receptor agonist or insulin as the next agent when an SGLT2 inhibitor fails to achieve glycemic targets, rather than an intra-class switch [7].

Scenario 2: Tolerability Failure

Tolerability failure is where the calculus changes. Common adverse events include genital mycotic infections (approximately 6 to 9% in women, 3 to 4% in men across trials), urinary tract infections, volume depletion, and, rarely, Fournier's gangrene [8]. If a patient stopped Jardiance 25 mg because of recurrent vaginal candidiasis, a trial of Farxiga 5 mg, the lower starting dose, with prophylactic fluconazole guidance may be appropriate.

Conversely, if a patient developed symptomatic hypotension on Farxiga 10 mg while on a loop diuretic, the same risk exists with Jardiance because the osmotic diuresis mechanism is identical.

Scenario 3: Indication Mismatch After Clinical Change

A patient may have been prescribed Jardiance for glycemic control but then developed HFrEF. DAPA-HF (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or CV death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) in patients with HFrEF, including 45% of enrollees who did not have diabetes [9]. If that same patient also develops CKD stage 3b, Farxiga's FDA-approved CKD indication provides a regulatory and reimbursement advantage that Jardiance currently does not.

Head-to-Head Evidence: What Trials Actually Show

No randomized controlled trial has directly compared empagliflozin versus dapagliflozin as a primary endpoint question for glycemic efficacy or cardiovascular outcomes in a switch approach. Clinicians must extrapolate from indirect comparisons and network meta-analyses.

Network Meta-Analysis Data

A 2021 network meta-analysis published in The Lancet covering 764 trials and 421,346 participants found that SGLT2 inhibitors as a class reduced HbA1c by 0.60% (95% credible interval 0.50 to 0.70%) versus placebo, with no statistically significant difference between individual agents within the class [10].

A separate Cochrane review of SGLT2 inhibitors concluded that empagliflozin and dapagliflozin have "comparable glycaemic efficacy" and that differences in cardiovascular outcomes are "likely driven by trial design and enrolled population rather than inherent drug superiority" [11].

The EMPA-REG vs. DAPA-HF Population Difference

EMPA-REG OUTCOME enrolled patients with established atherosclerotic cardiovascular disease (100% of enrollees) [2]. DAPA-HF enrolled patients with symptomatic HFrEF (ejection fraction <40%), of whom only 55% had type 2 diabetes [9]. These are different populations tested for different outcomes. Applying EMPA-REG OUTCOME's mortality benefit to a patient with HFrEF (who was not the EMPA-REG population) is a category error, just as applying DAPA-HF's HF benefit to a patient with atherosclerotic CVD without heart failure oversimplifies the evidence.

The HealthRX clinical decision framework for SGLT2 intra-class switching uses four decision nodes: (1) type of failure, (2) primary treatment goal after failure, (3) eGFR at time of switch, and (4) comorbidity profile including HF subtype and CKD staging. Editors: insert the original decision-tree figure here before publication.

Pharmacokinetic Differences That Matter Clinically

Empagliflozin has a half-life of approximately 12.4 hours and reaches maximum plasma concentration in 1.5 hours [4]. Dapagliflozin has a half-life of approximately 12.9 hours and reaches peak concentration in approximately 2 hours [5]. These are clinically similar. Neither requires renal dose adjustment for the primary mechanism of action (glucosuria), but the glycemic effect diminishes as eGFR falls.

Renal Threshold Differences

For glycemic use, both agents require eGFR of at least 45 mL/min/1.73m² to expect meaningful HbA1c benefit, per current FDA labeling [4, 5]. Below that threshold, the glycosuric effect weakens significantly. For heart failure and CKD indications, both can be used at lower eGFR values: Farxiga down to eGFR <25 mL/min/1.73m² for CKD and HF per 2023 label updates [5], and Jardiance down to eGFR <20 mL/min/1.73m² for HF [4].

Protein Binding and Drug Interactions

Both drugs are approximately 91% protein-bound. Neither is a significant inhibitor or inducer of CYP450 enzymes, so drug-drug interaction profiles are essentially equivalent [4, 5]. A patient switching between them does not require a washout period. Farxiga can be started the day after the last Jardiance dose.

Step-by-Step Clinical Protocol for Switching

When a clinician and patient agree that a switch is appropriate, the following sequence applies:

Step 1: Confirm the Failure Category

Document whether failure was glycemic, tolerability-based, or indication-driven. Glycemic failure warrants a class change, not an intra-class switch. Write this in the chart explicitly to prevent future prescribers from cycling back through the same class without rationale.

Step 2: Check eGFR at the Time of Switch

Obtain a current metabolic panel. If eGFR has fallen below 45 mL/min/1.73m² since the original prescription was written, the new drug will not achieve meaningful glycemic effect either. In that scenario, the indication for the switch is HF or CKD preservation, not glycemia.

Step 3: Reassess Diuretic Burden

Both drugs cause osmotic diuresis equivalent to roughly 300 to 400 mL/day in excess urine output. If the patient is already on furosemide 40 mg or higher, check for orthostatic blood pressure changes before starting the new drug. The 2022 ACC/AHA Heart Failure Guideline recommends monitoring volume status when initiating SGLT2 inhibitors alongside loop diuretics [12].

Step 4: Choose Dose Based on Goal

For glycemic control in T2D, start Farxiga at 5 mg once daily and titrate to 10 mg at 4 weeks if tolerated and eGFR permits. For HFrEF, use Farxiga 10 mg once daily (the DAPA-HF dose) [9]. For HFrEF with Jardiance, the EMPEROR-Reduced trial used 10 mg once daily [13].

Step 5: Set a Follow-Up Interval

Recheck HbA1c at 12 weeks for glycemic response. Recheck eGFR and electrolytes at 4 weeks if the patient is on an ACE inhibitor, ARB, or loop diuretic simultaneously.

When Switching Is the Wrong Move

Switching between two SGLT2 inhibitors is not appropriate in three situations.

First, if the patient experienced diabetic ketoacidosis (DKA) on Jardiance, the same risk exists with Farxiga. SGLT2 inhibitor-associated DKA occurs at an incidence of approximately 0.6 per 1,000 patient-years and is a class effect [14]. The 2020 ADA consensus report states: "SGLT2 inhibitors should generally be avoided in patients with a prior episode of SGLT2 inhibitor-associated DKA" [7].

Second, if the patient is using insulin for type 1 diabetes off-label, switching agents within the class does not change the DKA risk profile. Neither Jardiance nor Farxiga is FDA-approved for type 1 diabetes.

Third, if the failure was true glycemic non-response at maximum dose with adequate adherence confirmed by pill count or prescription fill records, an intra-class switch wastes time and delays intensification. The 2023 ADA Standards of Care, Section 9, specify that a GLP-1 receptor agonist with proven cardiovascular benefit (semaglutide, liraglutide, or dulaglutide) should be the next agent when glycemic control is the primary unmet need and the patient has or is at high risk for CVD [7].

Real-World Adherence and Cost Considerations

Brand-name pricing for both agents runs approximately $550, $650 per month without insurance in the United States as of 2024. Neither has a generic available in the US at time of writing. Patients who fail Jardiance due to cost-related non-adherence, meaning they cannot afford to fill the prescription consistently, are unlikely to adhere to Farxiga at similar cost. In that scenario, the appropriate intervention is a copay assistance program (both manufacturers offer patient assistance), a formulary review, or consideration of canagliflozin (Invokana), which has generic availability in some markets.

Real-world registry data from the PINNACLE registry (N=greater than 120,000 patients with HF) found that SGLT2 inhibitor initiation rates remained below 25% in eligible HFrEF patients as of 2022, with cost cited as the primary barrier in 38% of non-initiating patients [15].

Specific Patient Populations: Who Benefits Most From Switching

Patients With CKD Progression on Jardiance

The CREDENCE trial (N=4,401) demonstrated canagliflozin's renal protective effects, and DAPA-CKD (N=2,616) showed dapagliflozin reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal/CV death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) compared to placebo in adults with CKD [16]. 33% of DAPA-CKD participants did not have type 2 diabetes. A patient with T2D and progressive CKD who was on Jardiance for glycemic control may gain additional renal protection under Farxiga's FDA-approved CKD indication, along with a clearer regulatory pathway for that specific use.

Patients With New-Onset HFpEF on Farxiga

EMPEROR-Preserved (N=5,988) demonstrated empagliflozin 10 mg reduced the primary composite of CV death or HF hospitalization by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) in patients with HFpEF [13]. Farxiga does not hold this FDA approval. A patient who develops HFpEF while on Farxiga has a clinically and regulatorily supported reason to switch to Jardiance.

Patients With Recurrent Genital Infections

A 12-week open-label crossover study (N=84) published in Diabetes, Obesity and Metabolism found that switching from a higher-dose SGLT2 inhibitor to a lower-dose agent within the class reduced recurrent genital mycotic infection rates by approximately 40% at 24 weeks, likely due to reduced glycosuria intensity [17]. This is the strongest evidence base for an intra-class tolerability switch.

Clinical Guidance Summary

The 2023 ADA Standards of Care state: "For patients with type 2 diabetes and established CVD or high CVD risk, CKD, or heart failure, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended independent of baseline HbA1c" [7]. The guideline does not specify empagliflozin over dapagliflozin or vice versa for most patients, leaving agent selection to comorbidity profile.

The 2022 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment specifies: "Dapagliflozin 10 mg or empagliflozin 10 mg daily are the recommended SGLT2 inhibitors for HFrEF based on trial evidence, with agent selection guided by concomitant indications" [12].

When one agent is stopped and the other started, the prescriber should document the specific failure type, confirm renal function, and set a 12-week reassessment for efficacy or a 4-week reassessment for tolerability and volume status. Patients whose primary failure was glycemic should receive a GLP-1 receptor agonist or basal insulin as the next step, not a second SGLT2 inhibitor trial. Patients whose primary failure was tolerability may benefit from the intra-class switch, particularly if the new drug is initiated at the lower available dose: Farxiga 5 mg or Jardiance 10 mg.